Ranking Invest

GILD - Gilead Sciences, Inc.

Segmento: HealthcareGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Análise Ranking Invest

Valuation estimado
$ 40.93 Bi
Valor de Mercado
$ 167.92 Bi
Sobrepreço (AV)+310.3%
IVR
0.24A companhia vale 0,24 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
MLL
0.12A companhia gerou lucro líquido equivalente a 12% do seu valor de mercado nos últimos 4 trimestres.
Último Balanço Atualizado: 1T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 23.60 Bi

Dívida Líquida

$ 23.49 Bi

L4T

$ 9.22 Bi

MM4T

30.89%

Indicadores Básicos

ROE

39.05%

Índices de Previsibilidade

Faturamento

0.05

Lucro

0.20

Margem

0.17

Índices de Tendência

Faturamento

6.46

Lucro

7.20

Margem

6.72

Índices de Endividamento

DIV/PAT

1.00

DIV/L4T

2.55

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.